In addition, PD-L1 status was promising to predict prognosis, as PD-L1+ triple negative breast cancers were associated with significantly better progression-free survival compared with PD-L1− cancers (progression-free survival of 7.2 months vs. 5.5 months). Here, CD274 is linked to cancer.